It had previously undergone clinical trials as a treatment for severe sepsis [23], while IAXO-102 is a synthetic glycolipid that modulates TLR4 activation and signalling by interfering selectively with the TLR4 co-receptors CD14 and MD-2 [24]. The gene discussed is TLR4; the disease is Sepsis.